Similar articles

• Prehypertension: the rationale for early drug therapy.

  Fuchs FD. Fuchs FD. Cardiovasc Ther. 2010 Dec;28(6):339-43. doi: 10.1111/j.1755-5922.2010.00167.x. Cardiovasc Ther. 2010. PMID: 20553286 Review.
• Prehypertension and the cardiometabolic syndrome: pathological and clinical consequences.

  Duprez D, Toleuova A. Duprez D, et al. Expert Rev Cardiovasc Ther. 2013 Dec;11(12):1725-33. doi: 10.1586/14779072.2013.857272. Expert Rev Cardiovasc Ther. 2013. PMID: 24215200 Review.
• Prehypertension and risk of cardiovascular disease.

  Atilla K, Vasan RS. Atilla K, et al. Expert Rev Cardiovasc Ther. 2006 Jan;4(1):111-7. doi: 10.1586/14779072.4.1.111. Expert Rev Cardiovasc Ther. 2006. PMID: 16375633 Review.
• Blood pressure and antihypertensive therapy according to the global cardiovascular risk level in Italy: the CHECK Study.

  Filippi A, Casula M, Tragni E, Brignoli O, Cricelli C, Poli A, Catapano AL; CHECK Study Group. Filippi A, et al. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):562-8. doi: 10.1097/HJR.0b013e328338a4c6. Eur J Cardiovasc Prev Rehabil. 2010. PMID: 20308908
• Prognosis of Prehypertension Without Progression to Hypertension.

  Niiranen TJ, Larson MG, McCabe EL, Xanthakis V, Vasan RS, Cheng S. Niiranen TJ, et al. Circulation. 2017 Sep 26;136(13):1262-1264. doi: 10.1161/CIRCULATIONAHA.117.029317. Circulation. 2017. PMID: 28947482 Free PMC article. No abstract available.